Paper Details

  1. Home
  2. Paper Details

Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy.

Author: BatemanJ R, BulcavageL, ChlebowskiR T, LuceJ, ReynoldsR, WeinerJ M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study compared the long-term outcomes of two chemotherapy regimens for 112 patients with advanced breast cancer: 5-FU and CMF. While CMF initially showed better results in preventing cancer recurrence, more patients treated with 5-FU are currently alive. The study found that using combination chemotherapy after 5-FU failure often resulted in long-term survival, while long-term survival was uncommon after CMF failure. Patients receiving 5-FU were more likely to have relapses detected during regular checkups, suggesting a potential difference in tumor burden at the time of recurrence. Hormonal therapy or radiation therapy as initial treatment after relapse did not improve long-term survival. The study concludes that initial improvements in relapse-free survival may not predict long-term survival, as both the initial adjuvant therapy and the subsequent treatment after relapse can influence outcomes.
Paper Details　
Original Abstract of the Article :
Beginning in 1974, patients with greater than or equal to 4 nodes positive following mastectomy were randomized to receive either 5-FU i.v. weekly or CMF i.v. every 2 weeks, both given for 12 months. Median follow-up now exceeds 112 months with nine year results below: (table; see text) Early result...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF01886732

データ提供：米国国立医学図書館（NLM）

The Long Game: Survival After Relapse in Breast Cancer Treatment

This [study] takes us on a journey through the complex and challenging landscape of [breast cancer treatment]. It's like a desert expedition, following the path of patients who have faced the challenges of this disease and seeking to understand the factors that influence their long-term survival.

The study compared the long-term survival outcomes of patients who received different adjuvant therapies following [mastectomy] for [breast cancer] with [greater than or equal to 4 nodes positive]. The results showed that patients who relapsed after receiving [5-FU] adjuvant therapy had significantly better long-term survival compared to those who relapsed after receiving [CMF] adjuvant therapy. This suggests that the choice of adjuvant therapy may have a profound impact on long-term survival outcomes, even after relapse.

A Desert of Hope: Finding the Right Path to Long-Term Survival

This study highlights the importance of considering the long-term consequences of treatment decisions in breast cancer, reminding us that the journey to survival can be a marathon, not a sprint.

A Desert of Knowledge: The Ongoing Quest for Better Breast Cancer Treatment

This research underscores the need for continued research to understand the complex factors that influence long-term survival in breast cancer. It's like a desert expedition, where the journey of discovery never ends.

Dr. Camel's Conclusion

This study reminds us that the desert of breast cancer treatment is vast and complex, and that finding the right path to long-term survival requires careful consideration of all the options and a commitment to ongoing research.

Date :
  1. Date Completed 1986-06-02
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

3516262

DOI: Digital Object Identifier

10.1007/BF01886732

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.